Author:
Maraveyas A.,Dalgleish A. G.
Reference137 articles.
1. Acres, R.B., Hareuveni, M., Balloul, J.-M. and Kieny, M.P. 1993. Vaccinia virus MUC1 immunisation of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J.Immunother. 14: 136.
2. Aisner, J., Weinberg, M., Perloff, M., Weiss, R., Perry, M., Korzum, A., Ginsberg, S. and Holland, J.F. 1987. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CFM each +/− MER) for metastatic carcinoma of the breast: a CALGB study. J.Clin.Oncol. 5: 1523.
3. Anderson, J.M., Kelly, F., Gettinby, G. and Wood, S.E. 1977. Prolonged survival after immunotherapy (irradiated cancer autografts) for mammary cancers assessed by a measure of therapeutic deficiency. Cancer. 40: 30.
4. Anderson, J.M., Kelly, F., Wood, S.E. and Hainan, K.E. 1974. Stimulatory immunotherapy in mammary cancer. Br.J.Surg. 61: 778.
5. Asher, A., Mule, J.J., Kasid, A., Restifo, N.P., Salo, J.C., Reichert, C.M., Jaffe, G., Frendly, B., Krieger, M. and Rosenberg, S.A. 1991. Murine tumor cells transduced with the gene for tumor necrosis factor-a. Immunol. 146: 3227.